Product Name:AOD-9604
Cas No:221231-10-3
Application:a potential anti-obesity peptide based on human growth hormone
Molar Mass:1815.10
Chemical Formula:C78H123N23O23S2
Synonyms:LAT 8881
Storage:Store at -20°C
Sequence: YLRIVQCRSVEGSCGF
Target Indicators:Glucose-dependent insulinotropic polypeptide receptors
Purity:98%
Application:AOD-9604, also known as Tyr-hGH Frag 176-191, is a peptide derived from human growth hormone (hGH). It functions as a lipolytic agent, meaning it promotes the breakdown of fat cells, making it a promising candidate for obesity treatment and body fat reduction. Its mechanism of action involves stimulating the breakdown of stored fat and inhibiting the formation of new fat cells. AOD-9604 has garnered attention in the pharmaceutical industry for its potential in weight management therapies without affecting blood glucose levels. Additionally, it has shown promise in enhancing muscle mass and improving metabolism, making it valuable in sports medicine and fitness applications. In research, AOD-9604 is investigated for its role in treating metabolic disorders and promoting overall health and well-being.
Current Research:The WADA hGH isoform immunoassay is designed to detect the abuse of hGH in sports by binding different hGH isoforms to specific monoclonal antibodies, which are then detected using a labeled second antibody. AOD-9604’s classification as a fragment of hGH raises concerns about its potential interaction with the antibodies used in this assay. However, initial studies investigating the influence of AOD-9604 on the WADA hGH isoform immunoassay have shown promising results.
In these studies, different concentrations of AOD-9604 were tested on the hGH isoform immunoassay kits, and serum samples containing recombinant hGH were analyzed. Surprisingly, AOD-9604 did not bind to the antibodies of the assay, nor did it generate false-positive results for hGH. Furthermore, the peptide did not affect the test results of adverse analytical findings of hGH in serum samples. These findings suggest that AOD-9604 does not interfere with the detection assay for hGH in doping controls.
Moreover, additional investigations focused on the fortified serum samples containing recombinant hGH confirmed these results. The addition of AOD-9604 did not alter the concentrations of hGH isoforms detected by the assay, indicating that the peptide has no influence on the immunoassay’s ability to detect hGH. These findings remained consistent across different concentrations of AOD-9604 and with various hGH isoform immunoassay kits.
While these initial results are promising, further studies are needed to fully understand the pharmacokinetics of AOD-9604 in humans and its potential to be excreted into urine or plasma. If AOD-9604 is indeed excreted, modifications to existing peptide screening procedures may be necessary to detect the intact drug or its metabolites. Nonetheless, these findings provide valuable insights into the compatibility of AOD-9604 with existing doping control methods and underscore the importance of continued research in this area, especially in the context of anti-doping efforts in sports.
